Equities

Vicapsys Life Sciences Inc

VICP:PKL

Vicapsys Life Sciences Inc

Actions
  • Price (USD)0.444
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.08m
  • Incorporated1997
  • Employees2.00
  • Location
    Vicapsys Life Sciences Inc1735 Buford Highway, Ste. 215-113CUMMING 30041United StatesUSA
  • Phone+1 (470) 514-4013
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shineco Inc5.62m-14.34m13.34m87.00--0.3707--2.37-3.98-2.321.365.580.06640.481.4564,633.68-19.79-12.77-38.28-16.8412.7725.88-298.09-102.060.4842-8.140.3908-----58.35-33.86------
Monopar Therapeutics Inc0.00-7.61m13.44m10.00--1.80-----0.5289-0.52890.000.42770.00----0.00-73.36-54.07-92.67-60.60------------0.00------20.10------
Pieris Pharmaceuticals Inc40.93m-16.25m13.60m46.00--0.5798--0.3322-12.74-12.7434.0517.760.7324--28.25889,717.40-29.09-28.41-52.98-39.69-----39.71-94.61----0.00--65.288.0326.25---36.82--
CERo Therapeutics Holdings Inc0.00-2.54m13.63m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
Mannatech Inc127.23m-1.66m14.14m213.00--1.35--0.1111-0.899-0.89968.075.542.771.93561.74597,342.80-3.624.39-9.679.1678.0177.87-1.311.720.5584--0.138488.33-3.83-5.3350.13---20.38--
Vicapsys Life Sciences Inc0.00-1.08m14.24m2.00---------0.0327-0.03270.00-0.04160.00----0.00-364.66-----------------10.40---------317.25------
Organovo Holdings Inc242.00k-19.09m14.30m15.00--1.58--59.09-2.17-2.170.02750.62830.0143--4.4412,100.00-112.40-51.24-123.59-54.90-----7,886.36-1,269.78----0.00---75.33-39.60-50.76--5.99--
Galecto Inc0.00-30.83m14.51m13.00--0.5151-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Edesa Biotech Inc0.00-7.25m14.76m16.00--3.41-----2.37-2.370.001.340.00----0.00-84.50---107.87--------------0.00------52.28------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m14.77m103.00--0.1054--1.44-5.54-5.540.29561.470.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
Oncotelic Therapeutics Inc70.00k-7.79m14.79m22.00--1.25--211.26-0.0197-0.01970.00020.02960.0021--3.613,181.82-24.46-25.03-49.25-48.76-----11,536.00-1,692.93---0.46960.5341-------255.12------
Plus Therapeutics Inc (USA)6.08m-11.77m14.83m20.00------2.44-3.19-3.191.67-1.130.5724----304,200.00-110.75-59.18---133.04-----193.49-470.45--------2,093.30-5.8934.32--3.77--
Flora Growth Corp74.78m-47.58m14.87m97.00--3.32--0.1988-6.53-7.779.200.34941.485.9923.05770,958.80-92.50---140.01--21.72---62.66--0.6481--0.4952--127.75---1.87------
Traws Pharma Inc226.00k-18.16m15.04m16.00--2.08--66.53-0.8641-0.86410.01080.28530.0085--12.9114,125.00-68.21-63.43-104.99-85.72-----8,033.63-3,257.92----0.00--0.00-28.720.0844------
Data as of May 10 2024. Currency figures normalised to Vicapsys Life Sciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.